

# DUOGASTRONE<sup>®</sup>

## direct healing of duodenal ulcer

### Trials suggest\*

- radiological disappearance of ulcer crater
- relief of symptoms within a few days
- superiority over antacid or anticholinergic therapy
- patients can lead a normal life
- special diets are unnecessary
- even chronic cases, with a long history of symptoms, respond

Unique 'positioned release' capsules deliver the active ingredient (50 mg carbenoxolone sodium) into the duodenum.

\* Further trials are in progress to study the effects of DUOGASTRONE in long-term therapy




Full information available on request from


**Berk Pharmaceuticals Limited Godalming Surrey England**

Made under licence from Biorex Laboratories Ltd., London. Brit. Pat. Nos. 843,133 & 1,093, 286

® Regd. Trade Mark




## An inadequate barrier is no protection



Prolonged clinical evaluation has shown NOXYFLEX to be singularly effective against the intrusion of bacteria. NOXYFLEX literature outlines its proven uses in detail. Have you a copy?

**Protection: NOXYFLEX** 2.5G. Noxytiolin and 10 mgm. Amethocaine HCl  
**Geistlich Chester**

# This little tablet takes such a lot of trouble



# out of amylase testing

First of the Pharmacia diagnostic reagents for the determination of biologically active substances is the Phadebas amylase *tablet* test.


## Phadebas<sup>®</sup> Amylase Test

- No tedious preparation of reagents.
- Standardization—from tablet to tablet and bottle to bottle, reproducibility is certain. (Standard curve supplied).
- Accuracy ensured by entirely new type of starch substrate.
- Stability—no refrigeration required.
- Simplicity—less apparatus required.
- Rapidity of result.
- Highly sensitive.
- Highly precise.
- Wide range.
- Suitable for all body fluids.


Pharmacia (Great Britain) Limited  
Paramount House, 75 Uxbridge Road, London, W.5.  
Tel: 01-579 0102/7



Gastric ulcers—endoscopic photograph




# Gefarnil brings the ulcer problem down to size.



Traditional treatment in suspected or confirmed peptic ulcer cases is mostly symptomatic—geared simply to relief of pain.

Now there is Gefarnil—the unique healing agent. Its anti-ulcer properties have already been well established in animal experiments and clinical trials<sup>1,2,3</sup>. Its sys-

temic action means that Gefarnil can reach ulcer sites in both stomach and duodenum, and while many other agents act by surface contact, merely providing an environment for healing, Gefarnil takes effect through its blood-tissue level, independent of conditions in the gut lumen.



The expected sequence of events with Gefarnil is as follows:

- 15 days—remission of symptoms (usual antacid/antispasmodic treatment advisable during this period)
- 30 days—ulcers no longer detectable radiographically (but may still be evident endoscopically)
- 60 days—ulcers no longer detectable endoscopically.

Only minor transient side effects occur with Gefarnil, which can thus be used with confidence not only in confirmed but also in suspected ulcer patients.

Gefarnil\* is presented as capsules, each containing 50 mg. Gefarnate, and as injection solution, 50 mg. per ml.

Further information available on request.

<sup>1</sup> Arch. int. Pharmacodyn (1964), **147**, 113. <sup>2</sup> Minerva Gastroenterologica (1967), **13**, 157. <sup>3</sup> 4th World Congress Gastroenterology (1970).



# Gefarnil

60 DAYS' TREATMENT...THE RELIEF OF A LIFETIME



\* trademark

 The CROOKES  
Laboratories Limited  
Basingstoke, Hants

The  
long  
and the  
short

## of parenteral nutrition



The pre-and post-operative patient may require calories in the form of carbohydrates. These are best provided with minimal fluid volume. Just one litre of Sorbitol 30% 'Egic' provides your patient with 1200 calories, whereas three litres of the conventional dextrose 10% solution would be needed. Also with Sorbitol 30%—the risk of venous thrombosis is dramatically reduced and there is no danger of hyperglycaemia, or reactional hypoglycaemia, it has superior antiketogenic properties over fructose and is not insulin dependent. Sorbitol 30% 'Egic'—today's intravenous carbohydrate provider.

Sorbitol 30% 'Egic' Bottles of 500ml. Complete with giving set.

**Trophysan.** Wherever oral protein intake is insufficient Trophysan provides more readily assimilable free-amino nitrogen as pure crystalline amino acids in balanced proportions plus Sorbitol, Vitamins and Minerals. Trophysan often produces an earlier return to normal oral feeding and speeds recovery.

two better solutions for parenteral  
nutrition from Servier Laboratories ...




"In clinical practice Sorbitol has proved to be almost fully retained in the body and can replace intravenous dextrose as a carbohydrate source. Although like dextrose it yields only 4 cal. per gramme of carbohydrate, it can be safely administered as a 30 per cent solution containing 1200 cal. per litre. In a grossly infected surgical patient requiring intravenous feeding for 3 months, Sorbitol was used as the main source of calories without alteration in the patient's nitrogen balance."<sup>1</sup>

1. Reference: "The Utilisation and Metabolism of Intravenous Sorbitol"  
Brit. J. Surgery (1969), 56, 653.

Full information from  
**Servier Laboratories Limited,**  
*formerly Selpfarm Laboratories Ltd.*  
Percival House, Pinner Road, Harrow,  
Middlesex, HA1 4HQ.  
*products of L'Equilibre Biologique, France*

# Salazopyrin<sup>®</sup>

in the whole spectrum  
of ulcerative colitis ...



***mild... moderate...  
severe (fulminating)...  
relapse.***

"Among measures designed to prevent relapse small doses of corticosteroids are useless, and larger doses carry the risks of the therapy. (Salazopyrin) has been shown to reduce the relapse rate greatly when used in a maintenance dose ... over a period of one year".  
Brit. med. J. (1968) 2, 539-542, 605-607.

Salazopyrin (sulpha-salazine) is available as the plain 0.5 g. tablet, as the 0.5 g. EN-tab and as an 0.5 g. suppository.

Literature and detailed information on Salazopyrin are available on request.

Pharmacia (Great Britain) Ltd,  
Paramount House, 75 Uxbridge Road,  
London W.5.  
Telephone: 01-579 0102/7.

 Pharmacia

In all hospital trials the only Liquorice Therapy proved  
free from side effects

# CAVED-(S)

21 Hospital Trials Total 911 Patients

## DEFINITELY HEALS GASTRIC ULCERS

TODAY'S DRUGS . . . *BMJ* 1970 . 1 . 159-160

*"of proved therapeutic value"*

*"shown . . . to have antispasmodic effect"*

*" . . . does not alter serum level of sodium potassium or chlorine  
it does not cause retention of fluid"*

*"Healing of gastric ulcers was accelerated in patients to a statistically  
significant degree"*

*Gut* 1969 . 10 . 299-302

## THE EFFECTIVE THERAPY for DUODENAL ULCERS

*Duodenal ulcer cases showed marked symptomatic improvement. Statistical  
. . . beneficial effects in drug treated group.*

*Gut* 1968 . 9 . 48-51

### Very low cost!

- ★ No contra-indications
- ★ No dietary, alcohol or smoking restrictions
- ★ No bed rest
- ★ No additional antacids necessary

CAVED-(S) contains half normal dose of antacids, but compound tablet produced better *in-vivo* control than normal dose of antacid.

*Med Welt* 1963 . 18 . 1031-1034

Hospital trial with forty chronic D.U. patients (all referred for surgery) reports, after treatment with double the standard dose, none needed an operation and all were relatively symptom free over one year follow up. (Unpublished result)



Requests for representative to call or for samples and literature to:

**TILLOTTS LABORATORIES** - 94 MARSHAM STREET - LONDON SW1





# Mary is no surgeon

But the care and concentration which she gives to her work makes her an invaluable asset to ETHICON. Every day she attaches many thousands of needles to a wide variety of suture materials.

Mary had to pass extensive tests of ability and aptitude as well as strict eye tests for visual acuity—and now her skill helps ETHICON in its unceasing efforts to make a contribution to the growing practice of non-traumatic suturing in surgery.

'As the surgeon serves mankind, so ETHICON serves the surgeon'

**ETHICON**, LTD.

Edinburgh

# Duphalac<sup>®</sup>

Lactulose

## for a better response in patients with hepatic coma

---

### The Lancet 23rd April, 1966

Treatment of Chronic Portal Systemic Encephalopathy with Lactulose.

"Lactulose controlled neuropsychiatric symptoms as well as neomycin and produced no unpleasant side effects."  
... "Its action in preventing hepatic coma is presumably due to a change in bacterial flora secondary to chronic lowering of faecal pH, resulting in a decrease of production of toxic nitrogenous compounds in the colon."

---

### The Medical Journal of Australia 1968, 2:160 (July 27)

Treatment of chronic hepatic encephalopathy with Lactulose.

"... not adequately controlled by long term neomycin therapy and dietary protein restriction. Lactulose produced marked improvement, with disappearance of flapping tremor and construction apraxia, and the patients became fully conscious and mentally more alert. This improvement continued in spite of 70-80 grammes of protein per day in their diet."

---

### Tijdschrift voor Gastro-Enterologie 11,2, 1968.

Cirrhosis, Hyperammonaemia and Lactulose.

"Lactulose may replace neomycin with favourable results in these chronic cases, because it does not have the inconvenient side effects of neomycin such as bacterial resistance, hypersensitivity, secondary infection and moniliasis."

---

### The New England Journal of Medicine 281, 408-412, 1969

Lactulose in the treatment of chronic portal systemic encephalopathy. A double blind clinical trial.

"... lactulose proved effective in controlling chronic portal systemic encephalopathy, enabling neomycin to be discontinued and the daily intake of protein to be doubled."

---

### Australasian Annals of Medicine Vol. 18, No. 2, May 1969

Long-term treatment of portal systemic encephalopathy with lactulose.

"... our experience in the long term use of lactulose has been encouraging. It indicates that the drug is effective in controlling chronic and portal systemic encephalopathy and is a useful substitute for neomycin."

---


Duphalac syrup contains lactulose 50% W/W, lactose 5% W/W and galactose 8% W/W. Supplied in bottles of 200 ml. and 2 litres. Further information is available on request.

**duphar**

**DUPHAR LABORATORIES LIMITED BASINGSTOKE HANTS. TEL 0256 26351**  
DISTRIBUTORS IN EIRE - PHILIPS-DUPHAR (IRELAND) LIMITED RAINSFORD STREET DUBLIN 8 TEL DUBLIN 754271



# If you asked us we could write...



We could write your name on a label and send you a copy of the Alka-Seltzer book immediately. It makes instructive reading for the doctor who is interested in how his patients may be treating their minor ailments. Alka-Seltzer is an unusual product which has both antacid and analgesic effects. Its mode of action, its efficacy and its

safety are fully explained and documented in 'A Scientific Assessment of Alka-Seltzer'. If you would like a copy, please write to:  
Miles Laboratories Limited,  
Medical Dept. 11F, Stoke Court,  
Stoke Poges, Bucks.



Alka-Seltzer is a trade mark.

# RIFOCIN<sup>®</sup>-M


rifamide

LEPETIT

## in BILIARY TRACT INFECTIONS

"... it is unique in its action in acute cholecystitis and other bacterial diseases of the biliary tract, for which it is the only specific antibiotic."<sup>1</sup>

"A much higher proportion of the organisms found in cholangitis would be expected to be inhibited by this drug than by other antibiotics that achieve effective bile levels..."<sup>2</sup>



- \* Active against penicillinase-producing organisms.
- \* No cross-resistance or cross-allergenicity with other antibiotics has been demonstrated.
- \* Well tolerated. No toxic reactions have been reported.
- \* Dose: 150 mg intramuscularly every 8-12 hours.

RIFOCIN-M (rifamide) is a member of the RIFAMYCINS—a new group of antibiotics discovered and developed in the Research Laboratories of LEPETIT.

References: 1. *Med. J. Aust.*, 1966, 1, 1-7. 2. *Brit. J. Pharmacol.*, 1967, 31, 506-512.

Full information is available on request.



**LEPETIT Pharmaceuticals Ltd.**

Nicholson House, High Street, Maidenhead, Berks. Tel: Maidenhead 32277

# GASTRIC ULCER PATIENTS STILL FILLING YOUR BEDS?

For practical purposes conventional inpatient care of a gastric ulcer carries no ultimate advantage over ambulant therapy with carbenoxolone.

The Practitioner, 1969, 202, 402.

## BIOGASTRONE®

carbenoxolone sodium.

### frees beds and liberates the patient

Full information available on request.



**BERK PHARMACEUTICALS LIMITED**  
**GODALMING & SHALFORD SURREY**

Made under licence from Biorex Laboratories Ltd., London.  
Brit. Pat. No. 843, 133 R Regd. Trade Mark. J. 2995

*The FIRST book to cover ALL aspects of . . .*  
**Advanced Gastrointestinal Cancer**

Clinical Management and Chemotherapy

BY

*Charles G. Moertel, M.D., and Richard J. Reitemeier, M.D.*

Although the greater portion of the book is devoted to clinical research programs in chemotherapy and radiation therapy, the authors are keenly aware of the practical day-to-day problems met by the physician as he is called upon to administer supportive and symptomatic care. Special sections are devoted to pain control, management of edema and ascites, the control of nausea and vomiting, nutritional measures, assisting the patient's family, and pre-terminal care. Experienced specialists describe the palliative techniques employed by the general surgeon, the radiation therapist, the neurosurgeon, and anesthesiologist.

The second part of the book concerns the chemotherapy of advanced gastrointestinal cancer. Therapeutic agents, the fluorinated pyrimidines, are discussed in great detail including their administration, the relationship of their toxicity to the regression of cancer, and the clinical features influencing therapeutic responsiveness.

By **CHARLES G. MOERTEL, M.D.,** and **RICHARD J. REITEMEIER, M.D.,** both of the Mayo Graduate School of Medicine (University of Minnesota). With Seven Contributors from the Mayo Clinic. 236 pp., 48 illus., \$15.00

*Also available*

Dreiling, Janowitz and Perrier

**PANCREATIC INFLAMMATORY DISEASE**

A Physiologic Approach

"... a wealth of clinical experiences . . . are presented with clarity and authority . . . There are a number of good clear line drawings diagramming the operation in current use for chronic pancreatitis. This one short volume will become a useful reference source to everyone interested in pancreatitis . . . and in this area it provides an outstanding current review."  
 —S.G. & O.

By **DAVID A. DREILING, M.D.,** and **HENRY D. JANOWITZ, M.D.,** both of Mt. Sinai Hospital, New York; and **CLAUDE V. PERRIER, M.D.,** Clinique et Universitaire de Therapeutique, Geneva. 250 pp., 82 illus., \$10.50

Durham

**ENCYCLOPEDIA OF MEDICAL SYNDROMES**

"Once a physician has familiarized himself with this book he would probably not want to be without it." *J.A.M.A.*

"... an indispensable volume for anyone wishing to increase his knowledge while practicing medicine. It should be readily at hand for reference." *Archives of Internal Medicine.*

By **ROBERT H. DURHAM, M.D., F.A.C.P.,** Henry Ford Hospital, Detroit. 644 pp., \$15.00

*ORDER YOUR COPIES FROM*

HARPER & ROW, Publishers  
 49 East 33 Street

*Medical Department*  
 New York, N.Y., U.S.A. 10016

# ***TODAY'S DRUGS***

*New 1970 Edition*

The problem facing the prescribing doctor today is choice. Catalogues of drugs—no matter how detailed—are of little help unless accompanied by advice on which drug to give for what condition. So this new edition of “Today’s Drugs” not only gives a full account of the drugs but also includes clear accounts of the management of common conditions such as urinary infections and epilepsy.

The new edition differs from the earlier one in other ways. It deals with only three subjects— infections, vitamin deficiencies and anaemias, and disorders of the nervous system. Further volumes will be published at intervals of about a year, and by the time the whole field of therapeutics has been covered this first volume will have become obsolete and due for replacement. In order to further emphasize the ephemeral nature of books on therapeutics—and to cut costs—the book is a paperback.

*Demy Octavo*

*Paperback*

*224 pages*

**PRICE 20s. (U.S.A. \$3.00) including postage**

**ORDER YOUR COPY NOW FROM**

The Publisher, BRITISH MEDICAL JOURNAL, B.M.A. House,  
Tavistock Square, London WC1H 9JR, *or through any leading bookseller*

# **Selected Writings of Sir Arthur Hurst (1879-1944)**

Wordsworth said of Coleridge that he was like a torch to set other men alight and the same could be truly said of Sir Arthur Hurst. His case demonstrations drew an audience, not merely from Guy's Hospital and London, but from all over the world. It was characteristic that his younger colleagues took an active part in these demonstrations. He inspired many to engage with him in physiological and clinical research work in gastroenterology.

The originality and solidity of his contributions to gastroenterology have sometimes been underestimated just because of his other brilliant gifts. The present volume, which contains only a fraction of his published work, will correct any such misapprehension. It is surprising how much of our present knowledge of gastroenterology goes back to Hurst, as a glance at the Bibliography will show. Moreover, he set an example of the continuous process of discovery and re-appraisal, without which a subject cannot flourish. His inspiration has been transmitted directly to the present generation of gastroenterologists in Great Britain but ultimately it will have to depend on the written word. This memorial volume reveals the reasons for the pride and affection with which the British Society of Gastroenterology looks back to its founder, and ensures, as far as is humanly possible, that his personality and accomplishments will not be forgotten.

The British Society of Gastroenterology is grateful to Dr. Thomas Hunt for having prepared this memorial volume on its founder while many of his friends are still alive and his image is still vivid in our minds. The task has been a considerable one and has been notably well completed.

**Price 40s. (U.S.A. \$5.50) net**

*Copies can be ordered now direct from*

The Publishing Manager, GUT, BMA House, Tavistock Square,  
London WC1H 9JR, *or through any leading bookseller*



# SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Volume 5, No. 5, 1970  
CONTENTS

H. Petersen: <i>Relationship between Gastric and Pancreatic Secretion in Patients with Duodenal Ulcer</i> ..	321
C. Wasastjerna, C. J. Thodén, P. Ekelund & K. Haltia: <i>The Bile Canaliculi in Cytological Aspiration Biopsies from Patients with Liver Disorders</i> ..	327
Charlotte Erlanson: <i>p-Nitrophenylacetate as a Substrate for a Carboxylester Hydrolase in Pancreatic Juice and Intestinal Content</i> ..	333
R. Katterman & W. Creutzfeldt: <i>The Effect of Experimental Cholestasis on the Negative Feedback Regulation of Cholesterol Synthesis in Rat Liver</i> ..	337
A. Berstad: <i>A Modified Hemoglobin Substrate Method for the Estimation of Pepsin in Gastric Juice</i> ..	343
K. Nygaard, N. Helsingen & K. Rootwelt: <i>Adaptation of Vitamin B<sub>12</sub> Absorption after Ileal Bypass</i> ..	349
K. G. Wormsley: <i>Response to Duodenal Acidification in Man. III. Comparison with the Effects of Secretin and Pancreozymin</i> ..	353
J. Rask-Madsen & M. Schwartz: <i>Absorption of <sup>51</sup>Cr-EDT A in Ulcerative Colitis Following Rectal Instillation</i> ..	361
I. Borg & S. Emås: <i>Effect of Atropine on the Gastric Acid Response to Histamine and Pentagastrin in Conscious Cats</i> ..	369
M. Kekomäki, A. L. Schwartz & P. Pentikäinen: <i>Rate of Urea Synthesis in Normal and Cirrhotic Rat Liver with Reference to the Arginine Synthetase System</i> ..	375
N. Köster & P. Madsen: <i>The Intragastric Pressure Before and Immediately After Truncal Vagotomy</i> ..	381
B. J. Norlén, U. Krause & L. Bergman: <i>An Epidemiological Study of Crohn's Disease</i> ..	385
G. Dotevall, N. G. Kock & A. Walan: <i>Inhibition of Basal Gastric Acid Secretion in Man by Glucagon Given Intraperitoneally</i> ..	391
Charlotte Erlanson & B. Borgström: <i>Carboxyl Ester Hydrolase and Lipase of Human Pancreatic Juice and Intestinal Content. Behaviour in Gel Filtration</i> ..	395
E. Gjone, B. Fretheim, A. Nordøy, C. D. Jacobsen & K. Elgjo: <i>Intractable Watery Diarrhoea, Hypokalaemia, and Achlorhydria Associated with Pancreatic Tumour Containing Gastric Secretory Inhibitor</i> ..	401
L. S. Semb, E. Gjone & W. S. Rosenthal: <i>Bioassay for Gastric Secretory Inhibitor in Extract of Pancreatic Tumour from Patient with WDHA-Syndrome</i> ..	409
M.-P. Harri, W. Nienstedt & K. Hartiala: <i>Steroid Metabolism by the Canine Intestine. II. The Metabolism of Progesterone by the Jejunal Mucosa in Vitro</i> ..	415
M. Dalmark: <i>The Transmucosal Electrical Potential Difference across the Human Rectum in Vivo Following Perfusion of Different Electrolyte Solutions</i> ..	421
L. Carlborg, S. Dahlgren & B. Nordgren: <i>Gastric Secretion of Hydrochloric Acid and Sialic Acid in Patients with Peptic Ulcer and Gastric Cancer during Intravenous Infusion of Histamine</i> ..	427
G. Bendixen, N. Goltermann, S. Jarnum, K. B. Jensen, B. Weeke & H. Westergaard: <i>Immunoglobulin and Albumin Turnover in Ulcerative Colitis</i> ..	433
H. J. Fenger, E. Peitersen, D. Osterhammel, E. Gudmand-Høyer & J. Christiansen: <i>Vestibular Reactions during Dumping Provocation</i> ..	443
D. A. Aubrey & A. P. M. Forrest: <i>Comparison of the Gastric Secretory Responses Following the Administration of Histamine Acid Phosphate and Pentagastrin by Separate Continuous Intravenous Infusion or by a Step-test Method</i> ..	449
A. Berstad & H. Petersen: <i>Effect of Secretin on Histamine and Pentagastrin-induced Secretion of Pepsin in Man</i> ..	459
P. Rödbro, P. M. Christiansen & Å. Johansen: <i>The Secretion of Intrinsic Factor in Patients with Chronic Gastritis</i> ..	465
T. Scherstén, SV. Nilsson & E. Cahlin: <i>Current Concepts on the Pathogenesis of Human Gallstones</i> ..	473

Issued 30 June 1970

THE SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY publishes original papers in gastroenterology and pertinent fields of nutrition. Each issue contains about 80 pages; eight issues form one yearly volume. Supplements are supplied free of charge to subscribers. The subscription price including postage is N. kr. 150.-(\$25.-) payable in advance.

#### Editorial Correspondence

Manuscripts should be addressed to the managing editor. The Scandinavian Journal of Gastroenterology has no objection to the reproduction of short passages and illustrations from this journal without further formality than acknowledgement of the source.

#### Business Communications

Business communications, including subscriptions and orders for reprints or advertisements, should be sent to the publishers.

#### Publishers

UNIVERSITETSFORLAGET  
P.O. Box 307, Blindern, Oslo 3 Norway